A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Conditions: Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer
Interventions: Drug: BG-68501; Drug: Fulvestrant
Sponsors: BeiGene
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 25, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments